Comparative Pharmacology
Head-to-head clinical analysis: LEVOLET versus SYNTHROID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LEVOLET versus SYNTHROID.
LEVOLET vs SYNTHROID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Levolet (levothyroxine) is a synthetic thyroid hormone that replaces endogenous thyroxine (T4). It is converted to triiodothyronine (T3) in peripheral tissues, which binds to thyroid hormone receptors to regulate gene expression, increasing metabolic rate and protein synthesis.
Synthetic levothyroxine is a replacement for endogenous thyroid hormone. It binds to thyroid hormone receptors (TRα and TRβ) in the nucleus, regulating gene transcription involved in metabolism, growth, and development.
Levofloxacin 500 mg orally or intravenously once daily for 5-14 days depending on indication.
Initial adult dose 1.6 mcg/kg orally once daily, adjusted by 12.5-25 mcg increments every 6-8 weeks based on TSH levels. Maintenance dose typically 100-125 mcg/day.
None Documented
None Documented
Terminal elimination half-life: 6-8 hours; shorter in patients with hepatic impairment.
Levothyroxine (T4) terminal elimination half-life: 6-7 days in euthyroid patients; shortened to 3-4 days in hyperthyroidism and prolonged to 9-10 days in hypothyroidism; clinical context: supports once-daily dosing with steady-state reached after 6-8 weeks.
Renal: 70-80% unchanged, biliary/fecal: 20-30% as metabolites.
Renal: ~20-40% of T4 and T3 metabolites excreted in urine as glucuronide and sulfate conjugates; fecal: ~40-60% as unchanged drug and conjugates via biliary elimination; minor amounts in bile and feces as deiodinated products.
Category C
Category C
Thyroid Hormone
Thyroid Hormone